A comprehensive view of Oral Medicines / Supplements. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Roche announces positive Phase I results for oral GLP-1 receptor agonist CT-996; CT-996 shows -7.3% weight loss over four weeks, with safety profile consistent with other oral GLP-1 drugs
Published: July 17, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Pfizer advances with once-daily weight-loss pill danuglipron; company selects formulation for mid-stage trials after promising data from early-stage trial
Published: July 12, 2024 by CE Noticias Financieras
Pfizer advances once-daily formulation of oral GLP-1 receptor agonist Danuglipron obesity treatment; clinical evaluation shows promising pharmacokinetic data, dose optimization studies planned for late 2024
Published: July 11, 2024 by Pfizer Inc.
Lilly to acquire Morphic for $3.2 billion to enhance treatment for inflammatory bowel disease; acquisition includes lead program MORF-057 and expands Lilly's immunology pipeline with oral integrin therapies
Published: July 08, 2024 by Eli Lilly & Co.
AstraZeneca AB Files Patent Application for Pharmaceutical Formulations
Published: July 04, 2024 by Indian Patents News

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count